|
|
|
|
|
|
|
| Omnisense Offers Increased Accuracy in Fracture Risk Assessment |
|
Dusseldorf, Germany, MEDICA (November 16, 1999) Sunlight OmnisenseTM, Sunlight
Ultrasound Technologies' breakthrough device for the diagnosis of osteoporosis, increases
the specificity of fracture risk assessment, according to a study released last week.
The study, presented at the annual meeting of the American College of Rheumatology in
Boston, shows that changes in bone strength measurements vary at different skeletal sites. The researchers stated that single-site evaluation may sub-optimally estimate the skeletal involvement in
osteoporosis.
The Sunlight OmnisenseTM is a one-of-a-kind ultrasound device that measures bone strength
at multiple skeletal sites, enabling unprecedented accuracy and precision in the prediction of
fracture risk. In addition, the device is compact, cost-effective, user- and patient- friendly and
is easily installed in primary care facilities.
Osteoporosis is a global epidemic responsible for more than 1.5 million fractures annually. Eighty percent
of those affected by osteoporosis are women. In fact, a woman’s risk of hip fracture is equal
to her combined risk of breast, uterine and ovarian cancer. An average of 24% of hip
fracture patients aged 50 and older will die of complications in the year following their fracture.
While osteoporosis is often thought of as an older person’s disease, it can strike at any age.
All of this adds up to great costs in quality of life and huge healthcare expenses.
Osteoporosis is a treatable disease, but early detection of bone loss is crucial to
prevent fractures. With the help of the Sunlight OmnisenseTM, routine screening in the
comfort and security of the patient’s primary care doctor's office is now possible.
|
|
|
|
|
|
|
